Form 4: DSS Inc. Amends IBO Stock Sale Disclosure

DSS Inc. filed an amended Form 4 to correct its beneficial ownership of Impact Biomedical Inc. common stock following recent sales.

Summary

• DSS, Inc., identified as a 10% owner and director of IMPACT BIOMEDICAL INC. (IBO), filed an amendment to a previously submitted Form 4.
• The purpose of this amendment is to correct an error in the reported number of total shares of IBO common stock beneficially owned by DSS, Inc.
• The filing details two transactions where DSS, Inc. disposed of IBO common stock:
• On May 22, 2025, 115,600 shares were sold at a price of $0.5491 per share.
• On May 27, 2025, 45,400 shares were sold at a price of $0.5403 per share.
• Following these reported transactions, DSS, Inc.'s corrected beneficial ownership of IBO common stock is 545,024 shares.
• These beneficially owned shares include those acquired pursuant to the Celios Asset sale.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reported insider selling by a 10% owner and director, which can be perceived as a lack of confidence or a move to diversify. The need for an amendment to correct a previous reporting error also introduces a minor element of concern regarding disclosure accuracy.

Negatives

• DSS, Inc., a 10% owner and director, disposed of a total of 161,000 shares of IMPACT BIOMEDICAL INC. common stock across two transactions.
• The sales occurred at prices of $0.5491 and $0.5403 per share, representing a reduction in insider holdings.
• The filing is an amendment to correct a previous error in beneficial ownership reporting, which could indicate past inaccuracies in disclosures.

Future Outlook

This Form 4 amendment does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details an insider transaction and a correction to a previous disclosure, which is a routine regulatory requirement for publicly traded companies. It does not provide information directly related to broader industry trends or the competitive landscape of the biomedical sector.

Stakeholder Impact

• Shareholders: The sale of shares by a significant owner and director could be interpreted by shareholders as a negative signal regarding the company's future prospects or valuation, potentially influencing stock price.
• Regulatory Bodies: The amendment addresses a correction in beneficial ownership, ensuring compliance with SEC reporting requirements and maintaining transparency for regulatory oversight.

Key Dates

Keywords

Insider Trading, Form 4, Beneficial Ownership, Stock Sale, SEC Filing, IMPACT BIOMEDICAL INC., IBO, DSS INC., 10b5-1 Plan